(1) See definition of earnings before non-cash charges, a non-GAAP financial measure, and a reconciliation of net income to earnings before non-cash charges below. Expenses
The table below summarizes research and development expense by major project and non-project components (dollars in thousands):Three Months Ended September 30,20112010PercentageChangeProject and non-project component:Cardiopulmonary
8,2748,678(4.7) %Total research and development expense
40,33747.3%Cardiopulmonary. The increase in expenses related to our cardiopulmonary projects for the quarter ended September 30, 2011 was attributable largely to increases of $46.3 million in expenses incurred in connection with our July 2011 amended license agreement with Toray Industries, Inc. and $5.0 million incurred in connection with the closing of our license agreement with Pluristem Ltd.
Share-based compensation. The decrease in share-based compensation for the quarter ended September 30, 2011, compared to the same quarter in 2010, corresponded to a reduction in share-based compensation recognized in connection with our share tracking awards plans as a result of the decline in our stock price.
The table below summarizes selling, general and administrative expense by major categories (dollars in thousands):Three Months EndedSeptember 30,20112010PercentageChangeCategory:General and administrative
18,11837.8%Sales and marketing
(24,138)17,171(240.6) %Total selling, general and administrative expense
45,593(63.5) %General and administrative. The increase in general and administrative expenses for the quarter ended September 30, 2011, compared to the same quarter in 2010, corresp
|SOURCE United Therapeutics Corporation|
Copyright©2010 PR Newswire.
All rights reserved